Skip to main content
Premium Trial:

Request an Annual Quote


Correction: In last week’s issue, RNAi News incorrectly indicated that Effigene holds a patent covering the use of a quinolone to modulate the effect of an RNAi compound. In fact, the company has only filed certain claims related to the approach in US and European patent applications.